Landmark deal paves way for cheaper HIV protection jab

A landmark deal lowers the cost of a new HIV prevention drug to $40 annually, benefiting over 100 low-income countries. Lenacapavir, a groundbreaking injectable medication, offers six months of protection against HIV and holds potential to reduce new infections. Brokered by Bill Clinton, the agreement aims to increase global access to affordable HIV prevention and treatment, potentially helping end the HIV/AIDS epidemic.